ProCE Banner Activity

Phase II Study of Bomedemstat Plus Ruxolitinib for Patients With Myelofibrosis

Conference Coverage

Early evidence with bomedemstat plus ruxolitinib suggests favorable safety and efficacy for patients with MF following ruxolitinib or who were JAK inhibitor naive.

Released: December 12, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.